2018 POSTER PRESENTATIONS
Room: Grand Ballroom
Poster Presenters noted with † are Student Fellows.
Poster Presenters noted with * are Conference Speakers.
Presenting Wednesday through Friday
AbCellera Biologics, Inc.
101. A Versatile, High-Throughput Single Cell Screening Platform for the Generation of Fully Human Antibodies from Natural Immune Repertoires; Presented by Kevin H.*
AbCellera Biologics, Inc.
102. Unlocking Challenging Targets: Deep Screening of Natural Immune Repertoires at the Single-Cell Level for Therapeutic Antibody Discovery; Presented by Kevin H.*
Agilent Technologies
103. Determining Mechanisms of Mitochondrial Toxicity Using Agilent Seahorse XF Technology; Presented by Pamela S.
Ain Shams University
104. Potential Therapeutic Implications of Hematopoietic Stem Cell Gene Therapy in Correction of Mutation-Causing Human Beta-Thalassemia; Presented by Dina G.†
Antibody Solutions
105. A Novel Interface Targeted Discovery Engine for the Generation of Monoclonal Antibodies Against an Immune Checkpoint Cell Membrane Protein; Presented by John K.
AssayQuant Technologies, Inc.
106. Sensors for Continuous Monitoring of Protein Kinase and Phosphatase Activity; Presented by Erik S.*
Avacta Life Sciences
107. Generation of a Novel Affimer Biotherapeutic Targeting the PD-L1 Pathway to Deliver a Myeloid Selective Toxin to the Tumour Micro-Environment; Presented by Matthew V.
BellBrook Labs, LLC
108. The Transcreener® ADP[2] Assay: A Universal Kinase Assay for HTS and Lead Optimization; Presented by Meera K.
BellBrook Labs, LLC
109. Development of a High Throughput Transcreener Assay to Explore the Family of Ectonucleotidases Enzyme Family; Presented by Meera K.
BellBrook Labs, LLC
110. Sensitive Detection of PRMT4 Using Physiological SAM with the AptaFluor Methyltransferase Assay; Presented by Meera K.
Biodesy, Inc.
111. Second-Harmonic Generation Based Detection of Ligand-Induced Conformational Changes in STING; Presented by David S.
Biological Research Centre of the Hungarian Academy of Sciences
112. Predicting Antibiotic Resistance by Targeted Mutagenesis in Pathogenic Bacteria; Presented by Akos N.
Biomatters, Inc.
113. Advanced Antibody Analysis of NGS and Sanger Data from Selection and Screening Projects Accelerate Therapeutic Antibody Discovery; Presented by Cecilie B.
BPS Bioscience, Inc.
114. Improving Immunotherapy Through Assays of the Extracellular Adenosine Pathway; Presented by Pavel S.
Broad Institute of MIT and Harvard
115. Development of Subtype-Specific T-Type Calcium Channel Modulators for CNS Disorders; Presented by Joshua S.
Cellecta, Inc.
116. Cell Barcoding Libraries and Targeted Gene Expression for Single-Cell Genetic Analysis; Presented by Paul D.*
CELLGENTEK
117. Development of Interleukin-32 Gamma-Engineered Natural Killer Cells; Presented by Hyeran S.
Cellular Technology Limited
118. A Novel Fluorescence Based High-Throughput Target Cell Visualization Assay for Measuring Cell-Mediated Cytotoxicity; Presented by Villian N.
Charles River
119. A Translational Platform Using Primary Human Immune Cells In Vitro, Syngeneic and Humanized Models In Vivo to Support and Advance Immune-Oncology Drug Discovery; Presented by Barbara K.
Charles River
120. Two In Vitro Assays Relevant to Lung Fibrosis for Evaluating the Potency and Efficacy of Prospective Anti-Fibrotic Drugs; Presented by Lieke G.*
ChemBridge Corporation
121. Synthetic Macrocycle Library with Potential to Find Hits for CNS Drug Discovery Programs; Presented by Duncan B.
Chemspace, Inc.
122. Compound Libraries on Chemspace: An Approach to Chart Useful Regions in Available Chemical Space; Presented by Yurii M.
Chulalongkorn University
123. 5-Methylcytosine Containing CG Decamer as Z-DNA Embedded Sequence for a Potential Z-DNA Binding Protein Probe; Presented by Vorasit V.
CILcare
124. Role of Melatonin in the Prevention of Noise-Induced Hearing Loss; Presented by Sylvie C.*
Clarivate Analytics
125. Integrated Machine Learning Analysis of GWAS Loci to Assist Prioritization of Causal Genes for Parkinson's Disease; Presented by Cheng F.
Confluence Discovery Technologies
126. Development of Mitogen-Activated Protein Kinase Activated Protein Kinase-2 (MK2) Inhibitors Designed to Selectively Inhibit the p38/MK2 Complex; Presented by Joseph M.
Confluence Discovery Technologies
127. Using the Novel KINect Platform to Discover Drugs Targeting the Human Protein Kinase Cysteinome; Presented by William T.
Deutsches Elektron Synchrotron (DESY)
128. Characterization of Proteins of the SPI-1 Type III Secretion System of Salmonella thyphimurium; Presented by Ivonne B.†
Domain Therapeutics NA
129. bioSensAll™: Opening Up New Frontiers in RTK Drug Discovery; Presented by Guilhem D.
Eurofins Pharma Discovery Services
130. Interrogating Allosteric Interactions Using Multiple Readouts for GPCRs; Presented by Daniel B.
Eurofins Pharma Discovery Services
131. Multiple Pathway Activation in a Human M4 Muscarinic Receptor Cell-Based Assay; Presented by Carsten B.
Eurofins Pharma Discovery Services
132. Binding and Functional Analysis - Complementary Approaches in Safety Pharmacology; Presented by Thierry J.
Eurofins Pharma Discovery Services
133. Combining the Power of Different Profiling Approaches to Better Understand the Activity of Kinase Inhibitor Drugs; Presented by Alastair K.
Gachon University
134. Daurinol: A Novel Agent to Treat Inflammatory Arthritis via Induction of Regulatory T Cells and Suppression of Helper T Cells; Presented by Jungmin A.
GenScript USA, Inc.
135. Integrated Antibody Drug Discovery and Development: From Target to IND Application; Presented by Sasidhar M.
Glycotope GmbH
136. Tumor-Specific Carbohydrate Antigens as Preferable Targets for Novel Antibody Constructs; Presented by Timo L.
GVK Biosciences Pvt. Ltd.
137. Novel In Vitro Label-Free Medium to High-Throughput Screening Assays by RapidFire Mass Spectrometry; Presented by Lakshman R.
Integral Molecular
138. Discovery of Highly-Specific Claudin 6 Antibodies for Targeting Cancer; Presented by Ross C.
Integral Molecular
139. High-Resolution Epitope Mapping Reveals Antibody Mechanism of Action and Strengthens Intellectual Property; Presented by Joseph R.*
Integral Molecular
140. Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immuno-Oncology Targets; Presented by Sharon W.
Invivotek
141. Time and Strain-Related Variables of Multiple Dietary-Based Mouse NASH Models; Presented by Michael H.
iTeos Therapeutics
142. EOS100850, an Insurmountable and Non-Brain Penetrant A2A Receptor Antagonist, Inhibits Adenosine-Mediated T Cell Suppression, Demonstrates Anti-Tumor Activity and Exhibits Best-in-Class
Characteristics; Presented by Jakub S.
Key Organics Ltd.
143. New BIONET Compounds for CNS Diseases: Potent Brain Penetrant Compounds with Improved Physical Property Profile; Presented by Steve B.
Key Organics Ltd.
144. Building a Diverse and Experimentally-Curated Fragment Library; Presented by Steve B.
KU Leuven
145. Studying GPCR Signaling Using Cell-Based Impedance Technology; Presented by Jordi D.
Labcyte, Inc.
146. Detection of Phospho-Akt (Ser 473) as an Indication of PI3K Pathway Activation in MCF7 Cells Using the Labcyte Echo® Liquid Handler and Cisbio's HTRF® Cellular Assay Kit; Presented by Wayne L.
Labcyte, Inc.
147. High Throughput Multiplexed Apoptosis Assays Using the Labcyte Echo® Liquid Handler and the IntelliCyt® iQue Screener HD; Presented by Ward S.
Lifesensors, Inc.
148. Proteomic Discovery of Ubiquitylated Biomarkers for Neurodegenerative Disease; Presented by Peter F.*
Lifesensors, Inc.
149. New Developments in Ubiquitomics: Discovery of Poly-Ubiquitylated Proteins by Novel Chain-Selective TUBEs; Presented by Dominic V.
Ligand Pharmaceuticals, Inc.
150. Use of High Throughput SPR to Validate Next Generation OmniChickens; Presented by Kimberley B.
Ligand Pharmaceuticals, Inc.
151. Utilization of the OmniChicken™ Platform to Derive Functional Therapeutic Antibody Candidates Against a Transmembrane Protein Target; Presented by Darlene P.
Los Alamos National Laboratory
152. A Resistance-Proof Radioimmunotherapeutic Antibiotic Cocktail Against Plague; Presented by Antonietta L.
Masaryk University
153. Furo[3,2-b]pyridine - A Novel Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway; Presented by Vaclav N.†
Massey University
154. Characterization of Furazolidone-Resistant Escherichia coli Mutants Reveals Novel Reductase Activity of the AhpF Protein; Presented by Van Hung Vuong L.†
Medivir AB
155. Selective Suppression of Regulatory T-Cell Development Using Small Molecule Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1); Presented by Karolina E.*
Medivir AB
156. Identification and Characterization of Novel Small Molecule Inhibitors of Ubiquitin Specific Peptidase 1 (USP1); Presented by Daniel J.
MercaChem BV
157. Tankyrase Inhibitor Development: Evidence for Potential in Cancer Immune Therapy; Presented by Luc V.
ModiQuest Research B.V., An ImmunoPrecise Company
158. Selection of a Large Panel of Lead Antibody Candidates by High-Throughput Multiplex Screenings; Presented by Jos R.
Multispan, Inc.
159. Measure β-Arrestin Signaling Through Native GPCRs in High Throughput; Presented by Lisa M.*
Myongji University
160. Novel Carbapenemase Form Gram-Negative Pathogens as a Drug Target; Presented by Kwang Seung P.†
National Institutes of Health, National Center for Advancing Translational Sciences
161. Drug Repurposing Approach Identifies Synergistic Drug Combination Against Multi-Drug Resistant Acinetobacter baumannii;
Presented by Yu-Shan C.
National Institutes of Health, National Center for Advancing Translational Sciences
162. Identifying New Drug Targets by Illuminating the Druggable Genome; Presented by Karlie S.
Oxford Genetics Limited
163. Optimised CRISPR Vector Systems and Automated Library Construction Technologies for High-Throughput Cell Line Engineering and Screening Applications; Presented by Richard P.
Oxford Genetics Limited
164. A High Throughput Automated Platform for CRISPR Mediated Genomic Editing; Presented by Lee S.
PerkinElmer
165. Evaluating PD-1 and PD-L1 Blocking Antibodies Using Human and Mouse Binding Kits; Presented by Lindsay N.
PerkinElmer
166. LANCE Ultra TR-FRET-Based Detection and Modulation of Phosphorylated Protein Expression in Human Cells; Presented by Lindsay N.
Promega Corporation
167. Specific Detection of Target Cell Killing in Mixed Cultures Using HiBiT; Presented by Neal C.
Promega Corporation
168. Quantitative Live-Cell Characterization of PROTAC-Induced Degradation and Mechanism of Action; Presented by Steven E.
Promega Corporation
169. Broad Kinome Selectivity and Residence Time Profiling in Living Cells Using BRET; Presented by Matthew R.*
ProQinase GmbH
170. New Spontaneous and Carcinogen-Induced Mouse-Derived Isograft (MDI) Tumor Models for Immune Therapeutic Approaches; Presented by Katrin S.
Reaction Biology Corporation
171. Application of BRET Technology to Quantitatively Determine Kinase Inhibitor Potency in Live Cells; Presented by Yuren W.*
St. Jude Children's Research Hospital
172. Glucose-Dependent Regulation of Pregnane X Receptor Is Modulated by AMP-Activated Protein Kinase; Presented by Peter O.
Stanford University
173. Targeting MRSA Biofilms and Persister Cells with a New Antibiotic-Oligoarginine Conjugate; Presented by Alexandra A.†
Sygnature Discovery Ltd.
174. Application of Different Neuronal Cell Models to Investigate Glutamate-Induced Excitotoxicity in Drug Discovery; Presented by John U.
Taipei Medical University
175. Indole Based Phenylacrylamides with Potent HDAC Inhibitory, Anti-Proliferative and Anti-Angiogenic Activities; Presented by Samir M.†
Transomic Technologies, Inc.
176. A Genome-Wide Arrayed CRISPR Library for Studying Combinatorial Gene Interactions; Presented by Blake S.
Tufts University
177. Genetic Mechanisms of a Bacterial Predator Targeting Gram Negatives; Presented by Miles D.
Université de Sherbrooke
178. A Systematic Exploration of Macrocyclization in Apelin-13; Presented by Kien T.†
University College London
179. Use of Neuronal Oscillations in Brain Slices as a Biomarker to Characterise Drugs that Affect Cognitive Function; Presented by Thomas S.
University of Bergen
180. Druggable Genome in Attention Deficit/Hyperactivity Disorder and Its Co-Morbid Conditions: New Avenues for Treatment; Presented by Kai W.†
University of British Columbia
181. Peptidisc: A Simple Solution for Trapping and Stabilizing Membrane Proteins Without Detergent; Presented by Franck D.
University of California, San Diego
182. A Single Small Molecule Alleviates Tumor Burden by Targeting Dual Regulators of the 26S Proteasome; Presented by Sourav B.
University of North Texas Health Science Center
183. Design and Synthesis of Novel Irreversible Inhibitors of NGLY1; Presented by Nigam M.
University of Toronto at Scarborough
184. Single Domain Antibodies Targeting Motility of Enteric Pathogens Offers Protection in Livestock and Food Animals; Presented by Valencio S.
Vaccinex, Inc.
185. Use of Mammalian Virus Display to Select Antibodies Specific for Complex Membrane Antigens; Presented by Maria S.
Vanderbilt University
186. Pharmacological WDR5 WIN Site Inhibition in MLL Leukemia; Presented by Erin A.†
ZoBio B.V.
187. Design Principles of the ZoBio Fragment Library: Core Diversity and Synthetic Tractability; Presented by Jan S.
ZoBio B.V.
188. Protein Domain Trapping: High Throughput Protein Engineering to Enable Biophysics and Structural Biology Based Drug Discovery; Presented by Gregg S.
Presenting Wednesday through Thursday (morning)
Gyros Protein Technologies
201. Parallel Synthesis Optimization of Cyclic Peptides for Therapeutic Development; Presented by Cyf R.
H. Lee Moffitt Cancer Center and Research Institute
202. Landscape of Active Deubiquitinating Enzymes (DUB) in KRAS Mutant Lung Cancer; Presented by Shikha M.
Kyungpook National University
203. ASM Regulates the Autophagic Process by Controlling Lysosomal Biogenesis in Alzheimer's Disease; Presented by Jae-sung B.
Kyungpook National University
204. Neuronal SphK1 Acetylates COX2 and Contributes to Pathogenesis in a Model of Alzheimer's Disease; Presented by Hee Kyung J.
National University of La Rioja
205. Omega-3 Fatty Acids Administration Attenuates Neuropathic Pain Behaviors in Rats and Promotes Nerve Functional Recovery; Presented by Santiago U.†
Phanes Therapeutics, Inc.
206. Discovery of Anti-Apelin Mabs as Potential Therapies for Solid Tumors and Diabetic Retinopathy; Presented by Natalie W.†
RXi Pharmaceuticals
207. The Use of Self-Delivering RNAi (sd-rxRNAs) to Enhance NK Cell Cytotoxicity; Presented by Melissa M.
Salipro Biotech AB
208. The Salipro System for Detergent-Free Stabilization of Membrane Proteins; Presented by Andre H.
TetraGenetics, Inc.
209. TetraExpress™: A Platform for the Robust Expression and Purification of Correctly Folded and Functional Membrane Proteins; Presented by Alka A.
University of Queensland
210. Macrocyclization of Peptides by Selenoether Bridges: Synthetic Methods and Applications; Presented by Aline D.
Presenting Thursday (afternoon) through Friday
Albany Molecular Research, Inc.
301. Comparison of Neisseria Gonorrhoeae Minimum Inhibitory Concentrations Obtained Using Agar Dilution Versus Microbroth Dilution Methods; Presented by Rachael J.
American University of Beirut
302. Unveiling the Native Fingerprint of Bradykinin (B2) and Thromboxane (TP) Receptors Oligomerization in Vascular Cells; Presented by Oula D.†
Cayman Chemical Company
303. Study of Novel Aspartate Aminotransferase Inhibitor Binding Mechanism Through Structure-Based Mutational Analysis; Presented by Zahra A.
Edelris SAS
304. Exploring New Chemical Space Towards Hit Generation; Presented by Eric J.
Food and Drug Administration
305. Comparative Toxicity of Regorafenib and Its Pharmacologically Active Metabolites in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes and Hepatocytes; Presented by Qiang S.
Harvard Medical School
306. Using Protein Engineering to Map the Interface Between the Hormone Adiponectin and Its Receptor; Presented by Roberta P.
Life Chemicals, Inc.
307. Identification of Biologically Active Compounds as a Result of Screening Life Chemicals Compound Libraries; Presented by George B.
Life Chemicals, Inc.
308. Fragment Libraries for Drug Discovery; Presented by George B.
NeoProteomics, Inc.
309. High-Resolution Hydroxyl Radical Protein Footprinting Introduction and Workflow; Presented by John S.
TetraGenetics, Inc.
310. A Multiplatform Strategy for the Discovery of Conventional Monoclonal Antibodies that Inhibit the Voltage-Gated Potassium Channel Kv1.3; Presented by Yelena B.
Tulane University
311. Yeast as a Platform to Study Adenosine Receptor Signaling; Presented by Abhinav J.†
University of Oxford
312. Biotechnology: Pipeline Developments; Presented by Aleksandra S.†
Universitѐ De Rouen
313. Pharmacological Profiling of a New Melatonin Binding Site: MTx; Presented by Preety S.†
Westborough High School
314. Non-Specific Chemical Descriptor Based QSAR; Presented by Ananthan S.†